Skip to content
Optix Ventures UK provides expert analysis on technology in…

Zimbabwe Declines ‘Lopsided’ American Healthcare Assistance Deal Over Data Fears

Medical aid image
The proposed American funding was aimed at initiatives for HIV/Aids treatment and prevention, tuberculosis, and malarial diseases.

Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' demand for sensitive information.

This rejection was revealed following a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the arrangement was "unbalanced".

An official spokesman has since clarified that the United States was seeking health data for scientific study and profit but was unwilling to share the resulting advantages from any future treatments.

"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.

Her embassy indicated the United States had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.

A doctors' association in Zimbabwe has urged more negotiations to reach a agreement acceptable to all parties so the country's critical HIV treatment initiative can continue.

Wider Background

This development follows a similar situation in Kenya, where a high court suspended a similar deal with the US after concerns were filed about the security of Kenyans' medical information.

Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.

The agency had managed aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government deals to boost openness and responsibility.

According to statements, 16 African countries have so far agreed to similar agreements, constituting more than $18.3bn in new funding.

Specifics of the Rejected Deal

The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".

"We believe this partnership would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported programmes," Tremont commented.

However, official spokesman Nick Mangwana argued the proposed deal was "unfair".

"The proposal required Zimbabwe to surrender its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," he stated.

"In essence, our nation would supply the raw materials for medical research with no assurance that the resulting innovations would be accessible to our population should a new pandemic arise."

Sovereignty and International Frameworks

Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were upending systems already set up via the global health agency.

Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.

"This framework is designed to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."

Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.

"We are open to ongoing dialogue with our US partners on how subsequent co-operation could be designed in a way that respects the sovereignty and interests of both nations."

Health Experts Reaction

Medical experts expressed it recognised the official position, but suggested that talks must proceed given that a large portion of the country's HIV programmes depended on international support.

"If technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.

This impasse underscores the continuing challenges between accepting crucial foreign assistance and safeguarding a country's data in an ever more interconnected world.

CC
The writer

Christina Cohen

A venture capital analyst with over a decade of experience in tech startups and investment portfolio management across Europe.

Optix Ventures UK

Type to search articles.